These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35903564)

  • 1. Outcomes of COVID-19 in Inflammatory Rheumatic Diseases: A Retrospective Cohort Study.
    Alhowaish TS; Alhamadh MS; Alhabeeb AY; Aldosari SF; Masuadi E; Alrashid A
    Cureus; 2022 Jun; 14(6):e26343. PubMed ID: 35903564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 in patients with rheumatological diseases in the Eastern Province of Saudi Arabia.
    Alqatari S; Nemer A; Hasan M; Bukhari R; Al Argan R; Al Khafaji D; Alwaheed A; Alzaki A; Al-Wazza M; Al Warthan S; Al Saeed A; Albeladi F; Almeer H; AlSulaiman R; Abu Quren A
    J Med Life; 2023 Jun; 16(6):873-882. PubMed ID: 37675163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.
    Santos CS; Morales CM; Álvarez ED; Castro CÁ; Robles AL; Sandoval TP
    Clin Rheumatol; 2020 Sep; 39(9):2789-2796. PubMed ID: 32720259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 Mortality in Patients with Rheumatic Diseases: A Real Concern.
    Al-Adhoubi NK; Ali M; Wahshi HA; Salmi IA; Al-Balushi F; Lawati TA; Mohammed A; Muqbali AA; Kalbani HA; Al-Abrawi S; Khamis F
    Curr Rheumatol Rev; 2022; 18(3):234-242. PubMed ID: 35418287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sociodemographic and clinical factors associated with poor COVID-19 outcomes in patients with rheumatic diseases: data from the SAR-COVID Registry.
    Isnardi CA; Roberts K; Saurit V; Petkovic I; Báez RM; Quintana R; Tissera Y; Ornella S; D Angelo Exeni ME; Pisoni CN; Castro Coello VV; Berbotto G; Haye Salinas MJ; Velozo E; Reyes Torres ÁA; Tanten R; Zelaya MD; Gobbi C; Alonso CG; de Los Ángeles Severina M; Vivero F; Paula A; Cogo AK; Alle G; Pera M; Nieto RE; Cosatti M; Asnal C; Pereira D; Albiero JA; Savio VG; Maldonado FN; Gamba MJ; Germán NF; Baños A; Gallino Yanzi J; Gálvez Elkin MS; Morbiducci JS; Martire MV; Maldonado Ficco H; Schmid MM; Villafañe Torres JA; de Los Ángeles Correa M; Medina MA; Cusa MA; Scafati J; Agüero SE; Lloves Schenone NM; Soriano ER; Graf C; Pons-Estel BA; Gomez G; Landi M; De la Vega MC; Pons-Estel GJ;
    Clin Rheumatol; 2023 Feb; 42(2):563-578. PubMed ID: 36201124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation Into the Effect of COVID-19 Infection on Length of Hospital Stay and Mortality in Patients With Rheumatoid Arthritis.
    Thompson K; Shah A; Grunbaum A; Oyesanmi O
    Cureus; 2022 Feb; 14(2):e22685. PubMed ID: 35371748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study.
    Md Yusof MY; Arnold J; Saleem B; Vandevelde C; Dass S; Savic S; Vital EM; Emery P
    Lancet Rheumatol; 2023 Feb; 5(2):e88-e98. PubMed ID: 36712951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study.
    Avouac J; Drumez E; Hachulla E; Seror R; Georgin-Lavialle S; El Mahou S; Pertuiset E; Pham T; Marotte H; Servettaz A; Domont F; Chazerain P; Devaux M; Claudepierre P; Langlois V; Mekinian A; Maria ATJ; Banneville B; Fautrel B; Pouchot J; Thomas T; Flipo RM; Richez C; ;
    Lancet Rheumatol; 2021 Jun; 3(6):e419-e426. PubMed ID: 33786454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe COVID-19 in patients with immune-mediated rheumatic diseases: A stratified analysis from the SORCOM multicentre registry.
    Boteanu A; Leon L; Pérez Esteban S; Rabadán Rubio E; Pavía Pascual M; Bonilla G; Bonilla González-Laganá C; García Fernandez A; Recuero Diaz S; Ruiz Gutierrez L; Sanmartín Martínez JJ; de la Torre-Rubio N; Nuño L; Sánchez Pernaute O; Del Bosque I; Lojo Oliveira L; Rodríguez Heredia JM; Clemente D; Abasolo L; Bachiller-Corral J
    Mod Rheumatol; 2023 Dec; 34(1):97-105. PubMed ID: 36516217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?
    Santos CS; Férnandez XC; Moriano Morales C; Álvarez ED; Álvarez Castro C; López Robles A; Pérez Sandoval T
    RMD Open; 2021 Jan; 7(1):. PubMed ID: 33455920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between body-mass index, patient characteristics, and obesity-related comorbidities among COVID-19 patients: A prospective cohort study.
    Tong L; Khani M; Lu Q; Taylor B; Osinski K; Luo J
    Obes Res Clin Pract; 2023; 17(1):47-57. PubMed ID: 36577559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 and Pediatric Rheumatology: A Comprehensive Study from a Leading Tertiary Center in Saudi Arabia.
    Alqanatish J; Almojali A; Alfadhel A; Albelali A; Ahmed A; Alqahtani A; Alrasheed A; Alsewairi W; Alghnam S
    J Epidemiol Glob Health; 2023 Dec; 13(4):676-684. PubMed ID: 37594620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study.
    Pablos JL; Galindo M; Carmona L; Lledó A; Retuerto M; Blanco R; Gonzalez-Gay MA; Martinez-Lopez D; Castrejón I; Alvaro-Gracia JM; Fernández Fernández D; Mera-Varela A; Manrique-Arija S; Mena Vázquez N; Fernandez-Nebro A; ;
    Ann Rheum Dis; 2020 Dec; 79(12):1544-1549. PubMed ID: 32796045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics and COVID-19 outcomes in a regional cohort of pediatric patients with rheumatic diseases.
    Clemente D; Udaondo C; de Inocencio J; Nieto JC; Del Río PG; Fernández AG; Palomo JA; Bachiller-Corral J; Lopez Robledillo JC; Millán Longo C; Leon L; Abasolo L; Boteanu A
    Pediatr Rheumatol Online J; 2021 Nov; 19(1):162. PubMed ID: 34838054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of Hospital-related Outcomes of COVID-19 Infection in Patients With Inflammatory Bowel Disease in the Early Pandemic Phase: A Nationwide Inpatient Database Survey.
    Naseem K; Sohail A; Quang Nguyen V; Khan A; Cooper G; Lashner B; Katz J; Cominelli F; Regueiro M; Mansoor E
    Inflamm Bowel Dis; 2024 Aug; 30(8):1334-1344. PubMed ID: 37725039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the frequency and intensity of COVID-19 in patients with ankylosing spondylitis under anti-TNF therapy.
    Türk SM; Öztürk Z; Karataş D; Erkorkmaz Ü; Gönüllü E
    Turk J Med Sci; 2022 Apr; 52(2):522-523. PubMed ID: 36161620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases.
    Freites Nuñez DD; Leon L; Mucientes A; Rodriguez-Rodriguez L; Font Urgelles J; Madrid García A; Colomer JI; Jover JA; Fernandez-Gutierrez B; Abasolo L
    Ann Rheum Dis; 2020 Nov; 79(11):1393-1399. PubMed ID: 32769150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Demographic Characteristics, Comorbidities, and Length of Stay of COVID-19 Patients Admitted Into Intensive Care Units in Saudi Arabia: A Nationwide Retrospective Study.
    Al-Otaiby M; Almutairi KM; Vinluan JM; Al Seraihi A; Alonazi WB; Qahtani MH; Aljeri T; Alhumud MA; Alobaidi N; Alhurishi SA
    Front Med (Lausanne); 2022; 9():893954. PubMed ID: 35911421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omicron variant infection in inflammatory rheumatological conditions - outcomes from a COVID-19 naive population in Aotearoa New Zealand.
    Brooks J; Montgomery A; Dalbeth N; Sapsford M; Ngan Kee R; Cooper A; Quincey V; Bhana S; Gore-Massy M; Hausmann J; Liew J; Machado PM; Sufka P; Sirotich E; Robinson P; Wallace Z; Yazdany J; Grainger R
    Lancet Reg Health West Pac; 2023 Sep; 38():100843. PubMed ID: 37520279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study.
    Loarce-Martos J; García-Fernández A; López-Gutiérrez F; García-García V; Calvo-Sanz L; Del Bosque-Granero I; Terán-Tinedo MA; Boteanu A; Bachiller-Corral J; Vázquez-Díaz M
    Rheumatol Int; 2020 Dec; 40(12):2015-2021. PubMed ID: 32945944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.